Sustained Short Pressure on IBRX
ImmunityBio (IBRX) has been flagged for sustained settlement-level short pressure. Data derived from the FINRA Consolidated NMS short-volume file indicates that the stock has cleared the 50% short-volume ratio threshold for five consecutive trading days. This flow-based data suggests heavy intraday selling pressure rather than just a static open position. With a short interest of approximately 30.5% of the float and a days-to-cover ratio of 7.7, the stock remains a high-conviction target for short sellers. Investors should monitor the borrow fee, currently noted at 0.6%, for any sudden spikes that could indicate a tightening of lendable supply.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.